Combination of Glucagon-Like Peptide 1 Receptor Agonist and Thiazolidinedione for Mortality and Cardiovascular Outcomes in Patients With Type 2 Diabetes
In this cohort study of patients with type 2 diabetes, combination therapy with a GLP-1RA plus thiazolidinedione was associated with significantly lower hazards of mortality and cardiovascular complications compared with nonuse. The findings suggest that GLP-1RAs may mitigate the adverse cardiovascular effects of thiazolidinedione.
Authors
- Jingxing Li (ORCID: https://orcid.org/0000-0003-3776-5042)
- Chiung-Ray Lu
- Wei‐Hsin Chung (ORCID: https://orcid.org/0000-0002-8451-4011)
- Shu‐Bai Hsu (ORCID: https://orcid.org/0009-0009-9698-5695)
- Tzu-Ju Hsu (ORCID: https://orcid.org/0000-0002-2949-6535)
- Heng-Jun Lin (ORCID: https://orcid.org/0009-0003-1187-5494)
- Shinn‐Jye Liang
- Fuu‐Jen Tsai (ORCID: https://orcid.org/0000-0002-1373-245X)
- Kuan-Cheng Chang
Institutions
- Asia University (TW)
- National Taiwan University (TW)
- China Medical University (TW)
- China Medical University Hospital (TW)
- National Yang Ming Chiao Tung University (TW)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.2577
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59